No significant difference in terms of PFS (p = 0.406) or OS (p = 0.117) was observed between patients with KRAS G12C mutation subtype as compared to those with KRAS non-G12C mutation subtypes or with KRAS wild-type NSCLC (Figure S1). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.